Money on the markets

A maturing market amid the mayhem

Strides Arcolab jumps on deal talk

March 18, 2010


Shares in Strides Arcolab rose over 4 percent on Thursday after Aspen Pharmacare said it would sell its 50 percent stake in global oncology joint ventures to joint owner Strides for $117 million.

Shares in the counter rallied over 5 percent in intra-trade trade before ending 4.2 percent higher at 68.80 rupees with volumes of 28.29 million shares.

Strides vice chairman and group CEO Arun Kumar said the deal provided the Bangalore-based drug maker with greater focus and ownership of a key domain in its specialist division.

Strides has gained over 40 percent this year alone. Do you think it is the right time to invest in this counter?

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see